• PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • RARE Information Systems

    Nov 1, 2019, 00:00

  • PMU94 DATA GENERATED BY THE FRENCH COMPASSIONATE USE PROGRAM: HOW CAN THEY CONTRIBUTE TO THE HEALTH TECHNOLOGY ASSESSMENT?

    Nov 1, 2019, 00:00

  • PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PCN296 OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • Injury Trauma - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIH39 EVALUATION OF PROPRANOLOL OFF-LABEL USE IN INFANTILE HEMANGIOMA AND EFFECTIVENESS OF RISK MINIMISATION MEASURES TO MITIGATE ADVERSE REACTIONS: A FRENCH AND GERMAN DRUG UTILIZATION STUDY

    Nov 1, 2019, 00:00

  • PMD17 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM HIP BEARING SURFACES WHEN A HIP FRACTURE IS PRESENT AT ADMISSION IN THE 90 DAY EPISODE OF CARE

    Nov 1, 2019, 00:00

  • PIH57 THE BLEEDING AND PELVIC DISCOMFORT SCALE: MEASURING PATIENT-REPORTED SYMPTOMS IN UTERINE FIBROIDS

    Nov 1, 2019, 00:00

  • PCN174 BUDGET IMPACT OF LEUPROLIDE ACETATE 3-MONTHLY DEPOT FORMULATIONS FOR THE MANAGEMENT OF PATIENTS WITH ADVANCED AND METASTATIC PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

    Nov 1, 2019, 00:00

  • PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE

    Nov 1, 2019, 00:00

  • Surgery - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS249 HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE AND NORTH AMERICA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Infectious Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PIH54 HEALTH RELATED QUALITY OF LIFE OF PRE-ADOLESCENT DEAF CHILDREN WITH COCHLEAR IMPLANTS: A CONCEPTUAL DISEASE MODEL

    Nov 1, 2019, 00:00

  • PBI28 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • ND3 SHORT- AND LONG-TERM DISABILITY BURDEN AMONG EMPLOYED PATIENTS RECEIVING DISEASE-MODIFYING TREATMENT FOR MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PNS71 ROLE OF INFORMATION IN DEMAND FOR HEALTH SERVICES: AN INSTRUMENTAL VARIABLE APPROACH

    Nov 1, 2019, 00:00

  • Treatment Patterns Guidelines Studies

    Nov 1, 2019, 00:00

  • PDB112 EXPERIENCES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS PATIENTS IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PSU8 COMPARING COSTS OF USING FIBRINOGEN CONCENTRATE VERSUS FRESH FROZEN PLASMA IN THE TREATMENT OF BLEEDING DURING CARDIAC SURGERY IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN534 BARRIERS AND FACILITATORS TO IMPLEMENTING ELECTRONIC PATIENT-REPORTED OUTCOMES (PROS) IN CANCER CLINICAL TRIALS: INTERVIEW RESULTS FROM CLINICAL RESEARCH STAFF AND PATIENTS

    Nov 1, 2019, 00:00

  • PCN351 COMPARATIVE STUDY OF PFS AS PRIMARY ENDPOINT IN EUROPEAN HTA (FRANCE AND GERMANY)

    Nov 1, 2019, 00:00

  • What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges

    Nov 1, 2019, 00:00

  • PCN90 MANAGEMENT AND COST OF FEBRILE NEUTROPENIA (FN) IN THE ONCOLOGY PATIENT

    Nov 1, 2019, 00:00

  • CL3 THE ASSOCIATION BETWEEN TREATMENT INTENSITY AND ADHERENCE TO LIPID-LOWERING THERAPIES AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PRIMARY AND SECONDARY CARE: A SWEDISH REGISTRY-BASED STUDY

    Nov 1, 2019, 00:00

  • PCN100 HEALTH-ECONOMIC EVALUATION OF LUNG CANCER DRUGS: DO S AND DON TS IN FRANCE

    Nov 1, 2019, 00:00

  • PCN195 COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND GOSERELIN 1-MONTH FORMULATION AS ADJUVANT ENDOCRINE THERAPY IN POST-MASTECTOMY, PREMENOPAUSAL WOMEN WITH EARLY-STAGE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WHO ARE AT MODE ...

    Nov 1, 2019, 00:00

  • PMD49 MECHANICAL COMPLICATIONS ASSOCIATED WITH INTRAMEDULLARY NAILING FOR TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • Medical Devices - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO146 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY/ACTIVITY IMPAIRMENT IN PATIENTS WITH TRANSFUSION DEPENDENT B-THALASSAEMIA IN THE UK NHS: DATA FROM A UK MULTICENTRE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PDG25 ECONOMIC BURDEN OF OPIOID ABUSE IN THE USA

    Nov 1, 2019, 00:00

  • PRS4 SABA OVERUSE AND HEALTH CARE RESOURCE UTILIZATION IN A NATIONWIDE SWEDISH ASTHMA COHORT (HERA)

    Nov 1, 2019, 00:00

  • PSY11 ECONOMIC BURDEN OF PSORIASIS IN GREECE: RESULTS OF A MULTICENTRE, PROSPECTIVE, EPIDEMIOLOGICAL STUDY

    Nov 1, 2019, 00:00

  • PRO4 IMPACT OF ENZYME REPLACEMENT THERAPY ON THE RISK OF DEVELOPING GAUCHER DISEASE-RELATED COMPLICATIONS

    Nov 1, 2019, 00:00

  • PMD47 BREAKAGE OF INTRAMEDULLARY NAILING IN TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS?

    Nov 1, 2019, 00:00

  • New Frontiers in Oncology Cost Studies

    Nov 1, 2019, 00:00

  • PCN430 USING BAYESIAN METHODOLOGIES TO INFORM IMMATURE SURVIVAL EXTRAPOLATIONS BASED ON RWD AND EXPERT ELICITATION IN NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PNS88 THE "REHAB MAP” FOR INTERACTIVE PLANNING OF AMBULATORY REHABILITATION SERVICES

    Nov 1, 2019, 00:00

  • PCV74 COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • TP2 TREATMENT PATTERNS IN SPINAL MUSCULAR ATROPHY: INTERVIEWS WITH HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PIN51 ECONOMIC STUDY OF MEDICO-SURGICAL STRATEGIES IN PATIENTS WITH CHRONIC KNEE OR HIP PROSTHETIC JOINT INFECTION

    Nov 1, 2019, 00:00

  • PCV78 BURDEN OR ATRIAL FIBRILLATION AND BUDGET IMPACT OF DABIGATRAN IN ALGERIA

    Nov 1, 2019, 00:00

  • PMH51 BREXANOLONE INJECTION FOR THE TREATMENT OF POSTPARTUM DEPRESSION: MINIMAL IMPORTANT DIFFERENCE AND MEANINGFUL CHANGE

    Nov 1, 2019, 00:00

  • PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

    Nov 1, 2019, 00:00

  • PCN325 REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS: DIVERGENCE FROM EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PSU23 INTRAMEDULLARY NAILING OF FEMORAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PRO66 INCIDENCE AND PREVALENCE OF T-CELL LYMPHOMA IN THE EMA MEMBER STATES: METHODOLOGY FOR ESTIMATION IN RARE MALIGNANCIES OF CTCL AND PTCL

    Nov 1, 2019, 00:00

  • Multiple Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS275 SHOULD LIFECYCLE PRICING BE CONSIDERED IN HTA? PRACTICAL CONSIDERATIONS FOR INCORPORATION INTO HTA POLICY

    Nov 1, 2019, 00:00

  • PMH22 PREVALENCE OF DECISION ANALYTICAL MODELLING IN ECONOMIC EVALUATIONS OF MENTAL HEALTH INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCN349 VALUE OF INFORMATION ANALYSIS GUIDING THE REIMBURSEMENT DECISION OF OLAPARIB FOR METASTATIC BREAST CANCER

    Nov 1, 2019, 00:00

  • PCN477 APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY: RESULTS FROM A TOBIT REGRESSION

    Nov 1, 2019, 00:00

  • PNS361 THE TSQM: 15 YEARS OF USE

    Nov 1, 2019, 00:00

  • Mental Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN475 PERCEPTIONS AND EXPERIENCES OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: A UK CASE STUDY

    Nov 1, 2019, 00:00

  • PDB83 ANALYSIS OF PRESCRIPTION RATES OF INSULIN GLARGINE (IG), PER PRODUCT AND PRESENTATION TYPE, BY GENERAL PRACTITIONERS (GP) IN ENGLAND AND ITS ASSOCIATION WITH HEALTH DETERMINANTS (2013-2018)

    Nov 1, 2019, 00:00

  • PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS314 RELAXING THE MEMORYLESS PROPERTY WITHIN A MARKOV MODEL

    Nov 1, 2019, 00:00

  • PNS263 THE ROLE OF SURROGATES FOR PATIENT-RELEVANT ENDPOINTS IN THE EARLY BENEFIT ASSESSMENT IN GERMANY

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN263 ACCESS TO HEALTH SERVICES FOR PEOPLE WITH CANCER IN PERU: TRENDS IN SOCIO-ECONOMIC INEQUALITIES WITHIN THE FRAMEWORK OF A RESULTS-BASED BUDGETING PROGRAM

    Nov 1, 2019, 00:00

  • PND27 BUDGET IMPACT MODEL (BIM) FOR THE EQUISTASI® DEVICE

    Nov 1, 2019, 00:00

  • PNS389 VALIDITY OF THE HUNGARIAN TRANSLATION OF THE CARERQOL-7D INSTRUMENT AMONG INFORMAL CAREGIVERS IN THE HUNGARIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PSY29 EARLY-STAGE MYCOSIS FUNGOIDES: INCIDENCE AND DIFFERENTIAL SURVIVAL

    Nov 1, 2019, 00:00

  • PCV45 ATHEROSCLEROSIS: THE COST OF ILLNESS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PRO79 EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

    Nov 1, 2019, 00:00

  • PMH31 COST-EFFECTIVENESS OF GUIDED INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY IN COMPARISON WITH CARE-AS-USUAL FOR PATIENTS WITH INSOMNIA IN GENERAL PRACTICE

    Nov 1, 2019, 00:00

  • PNS407 PATIENT SELECTION PROCESS IN REAL-WORLD DATA FROM ELECTRONIC HEALTH RECORDS - SUGGESTED STANDARDISED PROCESS FOR SELECTING PATIENTS

    Nov 1, 2019, 00:00

  • PNS192 ASSESSING FACTORS ASSOCIATED WITH CATASTROPHIC HEALTH CARE PAYMENTS IN A WEST AFRICAN COUNTRY, CÔTE D'IVOIRE

    Nov 1, 2019, 00:00

  • PDG80 INFLUENCING FACTORS FOR A RENEWED BENEFIT ASSESSMENT IN THE GERMAN HTA PROCESS - A COMPARATIVE OVERVIEW OF §13 AND §14 IN CHAPTER 5 OF THE G-BA RULES OF PROCEDURE

    Nov 1, 2019, 00:00

  • PMU129 PERFORMANCE OF A COMPREHENSION QUESTION IN DISCRETE-CHOICE EXPERIMENT SURVEYS (DCE)

    Nov 1, 2019, 00:00

  • PMD48 OPPORTUNITIES AND CHALLENGES FOR NOVEL MEDICAL DEVICES LAUNCHING IN EUROPE IN THE HOSPITAL SETTING

    Nov 1, 2019, 00:00

  • PNS223 HEALTH-RELATED QUALITY OF LIFE DATA AVAILABILITY IN DRUG APPRAISALS IN FRANCE: WHERE DO WE STAND TODAY?

    Nov 1, 2019, 00:00

  • Infectious Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS320 ANALYSIS OF MINIMAL IMPORTANT CHANGE THROUGH ITEM RESPONSE THEORY METHODS

    Nov 1, 2019, 00:00

  • PBI59 THE REIMBURSEMENT STATUS OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Nov 1, 2019, 00:00

  • PGI53 A QUALITATIVE STUDY EXPLORING THE BURDEN OF ULCERATIVE COLITIS AMONG CHILD, ADOLESCENT, AND ADULT PATIENTS

    Nov 1, 2019, 00:00

  • PIN117 THE COST OF INFLUENZA RELATED HOSPITALIZATIONS IN ELDERLY IN TURKEY

    Nov 1, 2019, 00:00

  • PNS391 REAL WORLD USE OF VEHICLES BY OLDER PATIENTS TAKING SOLID ORAL MEDICATIONS: A SURVEY IN THE ONLINE HEALTH NETWORK PATIENTSLIKEME.

    Nov 1, 2019, 00:00

  • PCN462 ACCURACY OF RISK SCORING SYSTEM TO DETERMINE DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PIN107 ASSOCIATION BETWEEN NATURAL COLD REMEDIES AND ANTIBIOTIC THERAPY

    Nov 1, 2019, 00:00

  • PCV127 PATIENT PREFERENCES REGARDING ORAL ANTICOAGULANTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT IN SPANISH PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN-K ANTAGONISTS

    Nov 1, 2019, 00:00

  • PRO68 A SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

    Nov 1, 2019, 00:00

  • PCV5 3C-HF PROGNOSTIC SCORE TO PREDICT WORSENING CARDIAC FUNCTION AMONG CONGESTIVE HEART FAILURE PATIENTS IN UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • PRO102 ANALYSIS OF RECENT FRENCH HTA APPRAISALS OF ORPHAN DRUGS WITH OR WITHOUT CONTRIBUTION OF PATIENTS ASSOCIATIONS

    Nov 1, 2019, 00:00

  • PMU122 UPDATING DISABILITY WEIGHTS FOR MEASUREMENT OF HEALTHY LIFE EXPECTANCY AND DISABILITY-ADJUSTED LIFE YEAR IN KOREA

    Nov 1, 2019, 00:00

  • PDG46 DOES NEW WAY TO IMPROVE PATIENTS ACCESS TO EXPENSIVE INNOVATIVE DRUGS IN POLAND WORK?

    Nov 1, 2019, 00:00

  • PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2019, 00:00

  • PMS36 BUDGET IMPACT ANALYSIS OF TRIPLE THERAPY AFTER FAILURE OF METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2019, 00:00

  • PCN379 HTA ASSESSMENTS OF METASTATIC UROTHELIAL CARCINOMA TREATMENT IN EU COUNTRIES

    Nov 1, 2019, 00:00

  • PDB84 MANAGEMENT OF PREDIABETES FROM THE PERSPECTIVE OF SPANISH PHYSICIANS AND COMMUNITY PHARMACISTS. DETECTA2 STUDY

    Nov 1, 2019, 00:00

  • PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • New Frontiers in Health Technology Assessment Research

    Nov 1, 2019, 00:00

  • PCN256 RESULTS FROM THE CALIBRATION OF A MICROSIMULATION COLON CANCER SCREENING FRENCH MODEL

    Nov 1, 2019, 00:00

  • CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

    Nov 1, 2019, 00:00

  • PMS3 A COMPARATIVE ANALYSIS OF THE QUALITY OF LIFE OF PATIENTS TREATED WITH MINIMAL INVASIVE ANTERIOR HIP REPLACEMENT SURGERY AND NON-SURGICAL PATIENTS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS261 THE HEALTH ECONOMIC DOMAIN WITHIN HEALTH TECHNOLOGY ASSESSMENTS IN GERMANY — FIRST RESULTS AND ENSUING CONSEQUENCES OF THEMENCHECK MEDIZIN

    Nov 1, 2019, 00:00

  • PND16 A SEMI-STANDARDIZED SYMPTOM MENU TO FACILITATE GOAL ATTAINMENT SCALING IN DEMENTIA DRUG TRIALS: COMPARISON WITH TRADITIONAL APPROACHES

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCV67 BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN413 A BAYESIAN MIXTURE CURE MODEL USING INFORMATIVE PRIORS

    Nov 1, 2019, 00:00

  • PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PNS84 DEMOGRAPHIC FORECASTING WITH UNCERTAINTY OF POPULATION PROJECTION IN CYPRUS: A BAYESIAN PROBABILISTIC POPULATION PROJECTION STUDY

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS415 PUBLISHING OBSERVATIONAL STUDIES VS RANDOMIZED CONTROLLED TRIALS - A PUBMED REVIEW

    Nov 1, 2019, 00:00

  • PIN33 COST-EFFECTIVENESS OF CURRENT PNEUMOCOCCAL VACCINES IN OLDER ADULTS IN EUROPEAN SETTINGS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • SP2 DISCREPANCY IN HEALTH STATE UTILITY VALUES BETWEEN COST-UTILITY ANALYSIS AND REFERENCED ORIGINAL HEALTH UTILITY STUDIES IN CARDIOVASCULAR DISEASE: A REGISTRY-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • PNS123 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Nov 1, 2019, 00:00

  • PCN81 COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • CP4 META-ANALYSIS POWERED BY ARTIFICIAL INTELLIGENCE

    Nov 1, 2019, 00:00

  • PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE

    Nov 1, 2019, 00:00

  • PRO32 DE NOVO ECONOMIC MODEL TO ASSESS THE IMPACT OF SIZE AND DURABILITY OF EFFECT OF CURATIVE CELL AND GENE THERAPIES IN TREATMENT OF PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA)

    Nov 1, 2019, 00:00

  • PMU83 PATIENT-FOCUSED OUTCOMES IN THE AMNOG-PROCESS - STATUS QUO AND QUO VADIS

    Nov 1, 2019, 00:00

  • PNS373 IDENTIFICATION AND RECOMMENDATIONS OF READABILITY TESTS FOR THE EVALUATION OF CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PNS93 THE ACTUAL NUTRITIONAL STATUS OF SCHOOLCHILDREN IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PNS404 USING DATA WAREHOUSES TO OPTIMIZE HEALTHCARE DECISION MAKING

    Nov 1, 2019, 00:00

  • PCV20 MACHINE LEARNING BETTER PREDICTS RISK AFTER ACUTE CORONARY SYNDROMES, IDENTIFIES HIGH-COST INDIVIDUALS AND THOSE WITH ELEVATED BURDEN OF UNCONTROLLED RISK FACTORS

    Nov 1, 2019, 00:00

  • PRO108 ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS

    Nov 1, 2019, 00:00

  • PGI25 CLINIC AND ECONOMIC ANALYSIS FOR DIAGNISIS AND TREATMENT OF DIFFICULT BILE DUCT STONES WITH SINGEL OPERATOR CHOLANGIISCOPY IN TURKEY

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PSU26 ANALYSIS THE PROGRESSION OF MARKET SHARE OF ONE-DAY SURGERY AMONG HUNGARIAN UNIVERSITIES

    Nov 1, 2019, 00:00

  • PIN10 GROWTH FACTORS AND THEIR IMPACT ON HEALTHCARE UTILIZATION AND COST IN CACHECTIC HIV PATIENTS

    Nov 1, 2019, 00:00

  • PCN437 RECONSTRUCTION OF INDIVIDUAL PATIENT DATA FROM PUBLISHED SURVIVAL CURVES: CASE OF PRALATREXATE FOR PERIPHERAL T-CELL LYMPHOMAS

    Nov 1, 2019, 00:00

  • PNS251 FACTORS ASSOCIATED WITH THE OUTCOMES OF RAPID REVIEWS SUBMITTED TO THE NCPE

    Nov 1, 2019, 00:00

  • PCN102 DATA INTELLIGENCE FOR THE EVALUATION OF NEW TREATMENTS FOR BREAST CANCER: QUEST FOR A BETTER METHOD TO ESTIMATE AFFORDABILITY IN SCOTLAND

    Nov 1, 2019, 00:00

  • PRS9 HOW CLINICAL TRIALS INCORPORATED OUTCOMES RELEVANT FOR HEALTH ECONOMIC EVALUATION: AN EVIDENCE GAP ANALYSIS BASED ON SYSTEMATIC REVIEW OF CLINICAL TRIALS FOR MODERATE-TO-SEVERE ASTHMA IN JAPAN

    Nov 1, 2019, 00:00

  • PCN46 NOVEL APPROACHES TO ADDRESS RESISTANCE TO ANTI PD-1/PD-L1 THERAPY IN NSCLC

    Nov 1, 2019, 00:00

  • PUK17 EARLY CONVERSION FROM INTRAVENOUS TO ORAL ANTIBIOTICS: ASSESSMENT AND EVALUATION OF ECONOMIC OUTCOMES IN HOSPITALIZED PATIENTS

    Nov 1, 2019, 00:00

  • Drugs Regulatory

    Nov 1, 2019, 00:00

  • PNS219 TARGETED LITERATURE REVIEW AND PAYERS' PERSPECTIVES ON THE CURRENT PROGRESS OF HTA SYSTEM IMPLEMENTATION IN THE MENA REGION

    Nov 1, 2019, 00:00

  • PNS209 IMPACT OF GENERICS AND BIOSIMILARS ON BRANDED DRUG LISTING DECISIONS IN SINGAPORE

    Nov 1, 2019, 00:00

  • PNS405 DERIVING DATA FOR COST-EFFECTIVENESS MODELS FROM THE FRENCH SNDS DATABASE: A FEASIBILITY ASSESSMENT

    Nov 1, 2019, 00:00

  • PCN354 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • PRO106 A NEW MAJOR MARKET ACCESS CHALLENGE - KEEPING THE ROI WINDOW OPEN?

    Nov 1, 2019, 00:00

  • PND117 PATIENTS' PERSPECTIVES OF LIVING WITH MULTIPLE SCLEROSIS IN GREECE: AN INTERPRETIVE PHENOMENOLOGICAL ANALYSIS

    Nov 1, 2019, 00:00

  • PCN31 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN SECOND-LINE (2L) ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN ASIAN VERSUS WESTERN COUNTRIES

    Nov 1, 2019, 00:00

  • PND42 THE PRODUCTIVITY IMPACT OF EXCEEDING THE LEGAL TIME FOR PRICING AND REIMBURSEMENT DECISION OF ERENUMAB IN THE TREATMENT OF MIGRAINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN393 REVIEW AND VALIDATION OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL EXTRAPOLATION IN TECHNOLOGY APPRAISAL (TA) 366 BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PNS117 A STUDY ON THE FACTORS AFFECTING CHINESE CITIZENS' WILLINGNESS TO PURCHASE TAX-DEDUCTIBLE PRIVATE HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PRO138 PRODUCTIVITY LOSSES IN PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD EVIDENCE STUDY

    Nov 1, 2019, 00:00

  • PIN112 DISPARITIES AND SIMILARITIES IN THE INFLUENZA VACCINATION RECOMMENDATIONS ACROSS UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • PCN65 ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN

    Nov 1, 2019, 00:00

  • PSS8 EXTENDED LOADING DOSE OF ANTI-VEGF TREATMENT IN DIABETIC MACULAR EDEMA PATIENTS: A COST-CONSEQUENCE ANALYSIS

    Nov 1, 2019, 00:00

  • PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER

    Nov 1, 2019, 00:00

  • PNS256 PUBLIC VIEWS ON PRIORITY-SETTING CRITERIA FOR LIMITED HEALTHCARE RESOURCE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Cancer - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCV28 CHARACTERIZATION OF COSTS AND PATIENTS WITH INCIDENT HEART FAILURE (HF) INCURRING THE HIGHEST HEALTHCARE COSTS FROM SECONDARY CARE: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PRO151 PROJECT HERCULES: A MODIFIED DELPHI SURVEY TO INFORM A BURDEN-OF-ILLNESS STUDY IN DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • PND49 OUT-OF-POCKET EXPENSES IN MIGRAINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • RW3 HUMAN PAPILLOMA VIRUS IN ITALY: RETROSPECTIVE COHORT ANALYSIS AND VACCINATION EFFECT FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PCV137 ADHERENCE TO ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS OF A MULTI-COUNTRY STUDY

    Nov 1, 2019, 00:00

  • PCN513 RETROSPECTIVE STUDY DESCRIBING THE DEMOGRAPHIC CHARACTERISTICS, INCIDENCE, TREATMENT, COMORBIDITIES, MORTALITY, AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH MYELOFIBROSIS AND POLYCYTHEMIA VERA IN SWEDEN

    Nov 1, 2019, 00:00

  • PRO112 THE HST TEST: GOOD, BETTER, BEST?

    Nov 1, 2019, 00:00

  • PMU23 COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS DISEASE. COEPSO STUDY

    Nov 1, 2019, 00:00

  • PMS7 EFFICACY EXAMINATION OF PILATES TRAINING AMONG HEALTHY WOMEN ON THE CHANGE OF TRUNK STATE, POSTURE, LUMBAR MOTOR CONTROL ABILITY AND BALANCE

    Nov 1, 2019, 00:00

  • PCN53 CHECKPOINT INHIBITOR USE AND THE OCCURRENCE OF INSULIN-DEPENDENT OR DRUG-INDUCED DIABETES: WHAT CAN WE LEARN FROM REAL WORLD DATA?

    Nov 1, 2019, 00:00

  • PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00

  • PIN142 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH HIV

    Nov 1, 2019, 00:00

  • PDB47 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS) VS. HIPOS-ER (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - EMERGENCY ROOM) - A COMPARISON OF THE ECONOMIC OUTCOMES

    Nov 1, 2019, 00:00

  • PCN369 WHAT IS THE REGULATORY AND HTA LANDSCAPE OF NON-SMALL CELL LUNG CANCER DRUGS ACROSS THE EU5 COUNTRIES?

    Nov 1, 2019, 00:00

  • PMH53 IMPACT OF COGNITIVE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN CHINESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE PROACT STUDY

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMH61 NEUROLEPTIC THERAPY COMPLIANCE DIFFERS AMONG PATIENTS TREATED BY DIFFERENT PSYCHIATRISTS

    Nov 1, 2019, 00:00

  • ON2 VARIATION IN METHODOLOGICAL APPROACH TO PRODUCTIVITY COST VALUATION: DISTRIBUTIONAL EFFECTS IN THE CASE OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PCV142 ESTIMATING THE IMPACT ON RECURRENT HOSPITAL ADMISSIONS AND AMBULATORY VISITS OF PRESCRIBING FERRIC CARBOXYMALTOSE IN IRON DEFICIENCY PATIENTS WITH CHRONIC HEART FAILURE: A RETROSPECTIVE RWE STUDY USING A HOSPITAL REGISTRY IN SPAIN

    Nov 1, 2019, 00:00

  • AD2 DYNAMICS OF SWITCHING, ADHERENCE, AND PERSISTENCE OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS USE: AN AUSTRALIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN385 PAY-FOR-PERFORMANCE IN ONCOLOGY: A SUCCESSFUL STORY FROM BULGARIA

    Nov 1, 2019, 00:00

  • PDB28 A HEALTH ECONOMIC AND DECISION MODELLING ANALYSIS PLAN FOR AN INTEGRATED DATABASE OF OVER 100 CLINICAL TRIALS MEASURING HYPOGLYCAEMIC ATTACKS FOR PEOPLE WITH DIABETES: A HEDMAP FOR HYPORESOLVE

    Nov 1, 2019, 00:00

  • Table of Contents

    Nov 1, 2019, 00:00

  • PRS6 HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH SYMPTOMATIC COPD AND EXACERBATIONS IN CHILE: SUB-ANALYSIS OF THE IMPACT TRIAL

    Nov 1, 2019, 00:00

  • PMU124 ATTENDING PHYSICIAN MODELS OF CARE AND PATIENT OUTCOMES

    Nov 1, 2019, 00:00

  • PMD25 COMPARING ECONOMIC IMPACT OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN A SINGLE INSTITUTION IN THAILAND

    Nov 1, 2019, 00:00

  • PSS5 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN FRANCE

    Nov 1, 2019, 00:00

  • PSU42 PHARMACOVIGILANCE OF ANESTHETICS IN THE DEPARTMENT OF GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PNS160 ESTIMATING THE MARKET VALUE OF PERSONAL HEALTH RECORDS: THE CASE OF INDIVIDUAL DATA OWNERSHIP

    Nov 1, 2019, 00:00

  • PMU3 RISK FACTORS FOR ADVERSE DRUG REACTIONS IN PATIENTS UNDERGOING GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS333 EXTRAPOLATING SURVIVAL BY ASSUMING PROPORTIONAL HAZARDS BETWEEN GENERAL POPULATION MORTALITY AND DISEASE SPECIFIC MORTALITY

    Nov 1, 2019, 00:00

  • PCV69 COST EFFECTIVENESS ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN STEMI PATIENTS FROM NATIONAL HEART INSTITUTE PERSPECTIVE IN EGYPT

    Nov 1, 2019, 00:00

  • PND31 COST-EFFECTIVENESS ANALYSIS OF 5% LIDOCAINE PLASTER COMPARED TO PREGABALIN IN PATIENTS WITH POSTHERPETIC NEURALGIA IN CHINA

    Nov 1, 2019, 00:00

  • PND124 A REAL-WORLD DATA STUDY TO ANALYSE THE PHARMACOLOGICAL TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN SPAIN

    Nov 1, 2019, 00:00

  • PDB19 THE BIAS OF IGNORING CARDIOPROTECTIVE EFFECTS IN COST-EFFECTIVENESS ANALYSIS IN DIABETES

    Nov 1, 2019, 00:00

  • PIH20 A TARGETED LITERATURE REVIEW OF THE ECONOMIC BURDEN ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME

    Nov 1, 2019, 00:00

  • PIN61 ANALYSIS ON DIRECT MEDICAL EXPENSES OF PATIENTS WITH PULMONARY TUBERCULOSIS IN CHINA: BASED ON THE CASE OF 17,000 PATIENTS IN WUHAN

    Nov 1, 2019, 00:00

  • PIH21 COST-EFFECTIVENESS OF ORAL CARE IN INSTITUTIONALIZED OLDER PEOPLE

    Nov 1, 2019, 00:00

  • PRO36 BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV85 THE LONG-TERM EFFECT OF PARTICULATE MATTER(PM2.5, PM10) ON INCIDENCE AND MORTALITY OF MYOCARDIAL INFARCTION(MI): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMD32 STRUCTURE AND EVOLUTION OF THE FRENCH POSITIVE REIMBURSEMENT LIST FOR MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PMD4 SECONDARY CATARACT PROCEDURES DUE TO POSTERIOR CAPSULAR OPACIFICATION IN THE CZECH REPUBLIC: AN ANALYSIS OF HEALTH INSURANCE DATA

    Nov 1, 2019, 00:00

  • Surgery - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO119 A NOVEL MAPPING APPROACH FOR ESTIMATING UTILITIES IN NON-DYSTROPHIC MYOTONIA

    Nov 1, 2019, 00:00

  • CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE INADEQUATE RESPONDERS TO USTEKINUMAB: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMU109 HOW DO NICE EVIDENCE REVIEW GROUPS AND APPRAISAL COMMITTEES PERCEIVE FRACTIONAL POLYNOMIAL METHODOLOGY IN TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PMU59 ANALYSIS OF THE EVOLUTION IN THE ACCESS TO MEDICINES IN ITALY IN THE LAST 5 YEARS (2014-2018)

    Nov 1, 2019, 00:00

  • PIN47 FACING LIMITED ALTERNATIVES TO TREAT MULTI-DRUG RESISTANT BACTERIA IN THE FIELD OF NOSOCOMIAL PNEUMONIA

    Nov 1, 2019, 00:00

  • PND74 PREVALENCE OF PROGRESSIVE SUPRANUCLEAR PALSY (PSP) IN EUROPE, JAPAN AND THE USA

    Nov 1, 2019, 00:00

  • PNS260 INCLUSION OF NEW STRATEGIES IN THE UK'S CANCER DRUG FUND: WHAT WAS DECIDED IN FRANCE?

    Nov 1, 2019, 00:00

  • PDG35 RACE, SLEEP TESTING, AND TREATMENT DIFFERENCES BETWEEN NARCOLEPTIC PEDIATRIC POPULATIONS WITH AND WITHOUT CATAPLEXY: A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK ANALYSIS

    Nov 1, 2019, 00:00

  • PMU92 THE DANISH MEDICINE COUNCIL'S PROCESS OF ASSESSING NEW HOSPITAL MEDICINES: AN ANALYSIS OF DECISIONS 2017-2019

    Nov 1, 2019, 00:00

  • PMS42 PREVALENCE, PAIN INTENSITY AND DISABILITY OF LOW BACK PAIN AMONG INDIAN POPULATION. A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PCN54 EFFICACY AND SAFETY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED, ADVANCED STAGE MYCOSIS FUNGOIDES AND SÉZARY SYNDROME PATIENTS: A POST-HOC ANALYSIS OF THE MAVORIC STUDY

    Nov 1, 2019, 00:00

  • PCV139 EUROPEAN SURVEY ON STABLE ANGINA: REAL WORLD INSIGHTS ON PATIENTS’ CHARACTERISTICS, PERCEPTION OF DISEASE, AND QUALITY OF LIFE

    Nov 1, 2019, 00:00

  • PMU15 ECONOMIC IMPACT OF PREVENAR 13 VACCINATION AGAINST PNEUMOCOCCAL PNEUMONIA HOSPITALIZATIONS IN DANES 65+ WITH A CHRONIC DISEASE - A MODELLED ANALYSIS

    Nov 1, 2019, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN181 ACCELERATING EARLY COST-EFFECTIVENESS MODELING IN ONCOLOGY USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A RETROSPECTIVE CASE STUDY OF NIVOLUMAB PRE-TREATED METASTATIC SMALL-CELL LUNG CANCER POPULATION

    Nov 1, 2019, 00:00

  • Expanding Horizon of Outcome Studies in Oncology

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS210 NATIONAL HEALTH TECHNOLOGY SYSTEM (SINATS) IN PORTUGAL: 4-YEAR LANDMARK ANALYSIS

    Nov 1, 2019, 00:00

  • PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCV110 COST-EFFECTIVENESS OF SUTURELESS AORTIC VALVE REPLACEMENT VERSUS CONVENTIONAL AORTIC VALVE REPLACEMENT AND TRANSCATHETER AORTIC VALVE IMPLANTATION IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS205 SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PCN112 RESEARCH TREND OF THE PHARMACOECONOMIC STUDIES OF SMALL-MOLECULE PROTEIN KINASE INHIBITORS IN CHINA

    Nov 1, 2019, 00:00

  • PRS70 APPLYING DIFFERENT MEASURES TO ASSESS PATIENTS' NON-ADHERENCE: RESULTS OF A LINKED DATA STUDY OF PATIENTS WITH ASTHMA IN GERMANY

    Nov 1, 2019, 00:00

  • SP4 EXPLORING HETEROGENEITY IN PREFERENCES FOR ATTRIBUTES OF PHARMACEUTICAL TREATMENTS FOR OSTEOARTHRITIS AND CHRONIC LOW BACK PAIN IN THE UNITED KINGDOM: A LATENT CLASS APPROACH

    Nov 1, 2019, 00:00

  • PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER

    Nov 1, 2019, 00:00

  • PNS339 BAYESIAN NETWORK META-ANALYSES WHERE INFORMATIVE PRIORS WERE USED FOR THE BETWEEN-STUDY HETEROGENEITY; A PRAGMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS175 THE IMPACT OF RE-PRICING POLICY ON THE PRICE OF ANTI-CANCER DRUGS FROM 2007 TO 2017 IN SOUTH KOREA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PNS208 VALUE AND HEALTH TECHNOLOGY ASSESSMENT: TRANSPARENCY IN USE OF PEER-REVIEWED PUBLICATIONS

    Nov 1, 2019, 00:00

  • PIH47 COMPARISON OF CAESAREAN SECTION RATES IN GEOGRAPHICAL AREAS OF WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • PNS282 ANALYSIS OF METHODOLOGICAL LIMITATIONS RAISED BY THE FRENCH HEALTH TECHNOLOGY ASSESSMENT ON PUBLISHED EFFICIENCY OPINIONS FROM FEBRUARY 2014 TO MAY 2019

    Nov 1, 2019, 00:00

  • PCN386 GERMAN BENEFIT ASSESSMENT IN THE FIELD OF ONCOLOGY: FACTORS INFLUENCING THE BENEFIT RATING IN ADDITION TO COMPLYING WITH THE APPROPRIATE COMPARATOR

    Nov 1, 2019, 00:00

  • PND29 THE COST OF ACHIEVING NEDA WHILE USING TWO ALTERNATIVE FORMULATIONS OF INTERFERON BETA-1A FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN PORTUGAL: LET'S LOOK AT EVIDENCE

    Nov 1, 2019, 00:00

  • PMU24 ECONOMIC EVALUATION OF BIOCELLULOSE WOUND DRESSINGS FOR THE MANAGEMENT OF CHRONIC LEG ULCERS IN CANADA

    Nov 1, 2019, 00:00

  • PRO98 ULTRA-ORPHAN MEDICINAL PRODUCTS ASSESSMENT: COMPARISON OF THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) HTA FRAMEWORKS

    Nov 1, 2019, 00:00

  • PDG9 TRANSCON TECHNOLOGY: SOLVING UNMET NEED. VALIDATION IN PEDIATRIC GROWTH HORMONE DEFICIENCY

    Nov 1, 2019, 00:00

  • PBI18 ESTIMATION OF THE HEALTHCARE RESOURCE UTILIZATION (HCRU) COSTS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING TISAGENLECLEUCEL: A MICRO-COSTING STUDY IN THE UK AND FRANCE

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PIH12 VARIATIONS IN HEALTH INSURANCE AFFECT HEALTHCARE UTILIZATION IN CHILDREN WITH CROHNS DISEASE IN THE USA

    Nov 1, 2019, 00:00

  • PNS214 STEPS OF THE CREATION OF A HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PNS228 TIME FOR REIMBURSEMENT AND PRICING FOR DRUGS DEPENDING ON THE EARLY ACCESS STATUS IN FRANCE (WITH OR WITHOUT ATU)

    Nov 1, 2019, 00:00

  • PCV151 REAL WORLD EVIDENCE OF THE EFFECT OF PERIPHERAL ARTERIAL DISEASE (PAD) ON PATIENT HEALTH OUTCOMES AND COSTS IN AUSTRALIA.

    Nov 1, 2019, 00:00

  • PNS220 SUBMISSION PROCESS AND REQUIREMENTS OF NORDIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES FOR HOSPITAL DRUGS: IMPLICATIONS FOR MARKET ACCESS STRATEGY

    Nov 1, 2019, 00:00

  • PCN265 TARGETED REVIEW OF ADVERSE EVENTS ASSOCIATED WITH TREATMENTS FOR STAGE 3 AND 4 MELANOMA

    Nov 1, 2019, 00:00

  • PMU14 NON-MEDICAL SWITCHING AT THE HOSPITAL: A SYSTEMATIC REVIEW ON THERAPEUTIC CLASSES AND PATHOLOGIES THAT ARE APPROPRIATE TO ACHIEVE SAVINGS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMS35 EVIDENCE MAP OF ECONOMIC EVALUATIONS IN RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO27 IMPLICATIONS OF INDICATION EXPANSION OF ORPHAN DESIGNATED DRUGS ON EXISTING PRICES ACROSS EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • PNS67 WELLBEING VALUATION METHOD ON DETERMINING MONETARY VALUE OF WELFARE LOSS DUE TO HEALTHCARE ACCESS BARRIERS

    Nov 1, 2019, 00:00

  • PSY23 DIRECT COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN ALBERTA IN REAL WORLD

    Nov 1, 2019, 00:00

  • PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • Neurological Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PRO18 BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE

    Nov 1, 2019, 00:00

  • PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE

    Nov 1, 2019, 00:00

  • PGI4 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

    Nov 1, 2019, 00:00

  • PCN339 INCORPORATING COMPANION DIAGNOSTICS (CDX) IN COST-EFFECTIVENESS MODELS (CEMS) SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). A REVIEW

    Nov 1, 2019, 00:00

  • PNS46 POISSON REPRESENTATION OF MARKOV COHORT STATE-TRANSITION MODELS

    Nov 1, 2019, 00:00

  • PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF

    Nov 1, 2019, 00:00

  • PNS310 TRENDS IN CLINICAL TRIALS FOR DIGITAL HEALTH TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PBI50 LEVERAGING OUTCOME BASED AND PORTFOLIO AGREEMENTS TO GUARANTEE CLINICAL OUTCOMES: INNOVATIVE PAYMENT MODELS FOR HIGH COST ONE-TIME TREATMENTS

    Nov 1, 2019, 00:00

  • PMU98 UTILITY OF EARLY ACCESS TO MEDICINES SCHEME DATA FOR NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • Stated Preference Patient Satisfaction Research

    Nov 1, 2019, 00:00

  • PIH32 EPIDEMIOLOGIC FACTORS PREDISPOSING TO PEDIATRIC OBESITY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • PNS355 HOW INVOLVED SHOULD PAYERS BE IN THE DEVELOPMENTS OF TARGET PRODUCT PROFILE (TPP), PRODUCT DEVELOPMENT PLAN (PDP) AND DESIGN OF CLINICAL TRIALS (DOCT)

    Nov 1, 2019, 00:00

  • PBI69 INSIGHTS INTO FUTURE AUTOIMMUNE PRICING DYNAMICS IN EU5 THE US, USING LEARNINGS FROM RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PDG81 EARLY HEALTH TECHNOLOGY ASSESSMENT (HTA): LESSONS LEARNED FROM A RUSSIAN BIOTECHNOLOGY COMPANY

    Nov 1, 2019, 00:00

  • PCN282 ASSESSING THE EVOLUTION OF THE PRICING AND ACCESS LANDSCAPE FOR CELL AND GENE THERAPIES IN THE US AND EU3 THROUGH A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PCN288 HOW IS METASTATIC MELANOMA TREATED IN THE PUBLIC HEALTH SYSTEM IN BRAZIL?: A CALL FOR CHANGE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PRS39 THE ECONOMIC BURDEN OF ASTHMA

    Nov 1, 2019, 00:00

  • PNS329 ESTIMATION OF A DUTCH TARIFF FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT FOUR-LEVEL SELF-COMPLETION TOOL (ASCOT-SCT4)

    Nov 1, 2019, 00:00

  • PDB59 EVALUATING THE COST-UTILITY OF ADDING SODIUM-GLUCOSE COTRANSPORTER INHIBITORS TO A BASAL-BOLUS INSULIN REGIMEN IN PATIENTS WITH TYPE 1 DIABETES IN THE UK: AN ANALYSIS USING THE PRIME DIABETES MODEL

    Nov 1, 2019, 00:00

  • PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?

    Nov 1, 2019, 00:00

  • PBI74 MARKET ACCESS LANDSCAPE FOR BIOSIMILARS IN SWEDEN: AN UNTAPPED POTENTIAL?

    Nov 1, 2019, 00:00

  • PNS52 ASSESSMENT OF THE IMPACT OF THE LEVEL OF ASMR ON THE DRUG'S PRICE AND ITS NEGOTIATION TIME WITH THE HEALTH AUTHORITIES IN TREATMENTS THAT BENEFITED FROM THE FRENCH EARLY ACCESS PROGRAM

    Nov 1, 2019, 00:00

  • PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS

    Nov 1, 2019, 00:00

  • PNS305 PATIENT-LEVEL SIMULATION MODELS: THE POWER OF PARALLEL WORLDS

    Nov 1, 2019, 00:00

  • PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

    Nov 1, 2019, 00:00

  • PCN377 WHERE DO WE GO WITH WHOLE GENOME SEQUENCING IN ONCOLOGY? USING SCENARIO DRAFTING TO EXPLORE FUTURE DEVELOPMENTS

    Nov 1, 2019, 00:00

  • PCN484 SYSTEMATIC REVIEW OF A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN PATIENTS WITH MULTIPLE MYELOMA: EORTC QLQ-MY20 INSTRUMENT DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • PIN52 STUDIES REPORTING COSTS ASSOCIATED WITH INVASIVE MENINGOCOCCAL DISEASE IN EU-27: METHODOLOGY AND OUTCOMES

    Nov 1, 2019, 00:00

  • PND114 REAL WORLD PATIENT SURVEY ON HOW MIGRAINE AFFECTS EGYPTIAN SOCIAL AND WORK LIFE

    Nov 1, 2019, 00:00

  • PMD11 MEASURING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN XIAMEN, CHINA

    Nov 1, 2019, 00:00

  • PAM6 BUDGET IMPACT ANALYSIS OF THE ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN OBESE PATIENTS IN ITALY

    Nov 1, 2019, 00:00

  • PNS237 CLINICAL OUTCOME ASSESSMENTS AS A CONDITION IN HTA RECOMMENDATIONS: THE CANADIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • TP3 CHARACTERIZING AND COMPARING US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY RECEIPT OF MEDICATION-ASSISTED TREATMENT (MAT)

    Nov 1, 2019, 00:00

  • PCN490 MAKING OUTCOME-BASED PAYMENT A REALITY IN THE NATIONAL HEALTH SERVICE FOR ENGLAND

    Nov 1, 2019, 00:00

  • PND63 ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON'S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PND86 COST-UTILITY ANALYSIS OF DELTA-9-TETRAHIDROCANNABINOL AND CANNABIDIOL OROMUCOSAL SPRAY

    Nov 1, 2019, 00:00

  • PCN345 A REVIEW OF DIFFERENCES IN DECISION-MAKING ACROSS NICE HEALTH TECHNOLOGY ASSESSMENTS OF NIVOLUMAB

    Nov 1, 2019, 00:00

  • RE4 IS MARKET ACCESS FOR ONCOLOGY TREATMENTS EASIER IN ENGLAND THAN FOR NON-ONCOLOGY TREATMENTS? AN ANALYSIS OF NICE SINGLE TECHNOLOGY APPRAISALS FROM 2017-2019

    Nov 1, 2019, 00:00

  • PCN106 A REVIEW OF DECISION ANALYTIC MODELS TO EVALUATE THE COST-EFFECTIVENESS OF CANCER TREATMENTS: 5-YEARS OF PUBLICATIONS AND SINGLE-TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PRO80 COMPARISON OF EARLY ACCESS PROGRAMMES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES

    Nov 1, 2019, 00:00

  • Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England

    Nov 1, 2019, 00:00

  • PND61 DIRECT AND INDIRECT COSTS OF MIGRAINE IN HEADACHE SPECIALIST CENTERS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS185 RELATIONSHIP BETWEEN PARTIAL VALUES AND SCORING SCALE FOR EACH CRITERION OF THE EVIDEM 10TH EDITION CORE MODEL IN JAPAN

    Nov 1, 2019, 00:00

  • PCN8 EXAMINATION OF FACTORS INFLUENCING THE OCCURRENCE OF THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS (MPN) BASED ON HUNGARIAN NATIONAL REGISTRY DATA

    Nov 1, 2019, 00:00

  • PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS

    Nov 1, 2019, 00:00

  • CL4 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF THE EFFICACY AND TOLERABILITY OF APALUTAMIDE AND DAROLUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • HT2 IS THERE POTENTIAL FOR JOINT HEALTH TECHNOLOGY ASSESSMENT (HTA) IN EUROPE? AN EVALUATION OF EUNETHTA JOINT CLINICAL ASSESSMENTS VS. NATIONAL APPRAISALS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN209 END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE: A HOSPITAL-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PND35 CLINICAL AND ECONOMIC BURDEN OF MIGRAINE IN SPAIN, FRANCE, AND THE UNITED KINGDOM: RESULTS OF A POOLED ANALYSIS

    Nov 1, 2019, 00:00

  • PNS198 PHARMACY COST OF PREVENTING ADVERSE DRUG EVENTS BY PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS

    Nov 1, 2019, 00:00

  • PNS216 NICE HIGHLY SPECIALISED TECHNOLOGY ASSESSMENT: HOW ARE SELECTION CRITERIA APPLIED IN PRACTICE?

    Nov 1, 2019, 00:00

  • PGI6 TREATMENT FAILURE AND REMISSION IN MODERATE TO SEVERE ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) IN EUROPE

    Nov 1, 2019, 00:00

  • PNS16 IMPROVING ACCESS TIME IN NUCLEAR CARDIOLOGY TOWARDS QUALITY DELIVERY OF HEALTHCARE SERVICES

    Nov 1, 2019, 00:00

  • PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PMH60 ASSESSMENT OF THE INTERNAL CONSISTENCY AND CONCURRENT VALIDITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN AN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER POPULATION-BASED SAMPLE

    Nov 1, 2019, 00:00

  • PCN240 POTENTIAL BUDGET IMPACT OF ADJUVANT TREATMENTS FOR STAGE III MELANOMA IN IRELAND

    Nov 1, 2019, 00:00

  • PGI57 NON-BIOLOGIC TREATMENT OF GERMAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF HEALTH CARE RESOURCE USE AND COST ASSOCIATED WITH DISEASE ACTIVITY

    Nov 1, 2019, 00:00

  • PNS72 EVALUATION OF MEDICAL TECHNOLOGIES WITH UNCERTAIN BENEFITS

    Nov 1, 2019, 00:00

  • Neurological Disorders Studies

    Nov 1, 2019, 00:00

  • PCN387 ARE NICE APPRAISAL COMMITTEES BEING CONSISTENT IN THEIR IMPLEMENTATION OF THE END OF LIFE CRITERION?

    Nov 1, 2019, 00:00

  • PBI91 CHARACTERISTICS AND MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) PATIENTS IN A LARGE REPRESENTATIVE REAL WORLD COHORT

    Nov 1, 2019, 00:00

  • PNS377 BARRIERS AND ENABLERS TO PATIENT ENGAGEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS: AN IRISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU107 INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND

    Nov 1, 2019, 00:00

  • PNS146 WHAT APPROACH SHOULD BE TAKEN IN ORDER TO EFFECTIVELY MANAGE BEHAVIORAL HEALTH RISK FACTORS? A CONSENSUS PANEL ANALYSIS FOR GREECE

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Organizational Practices

    Nov 1, 2019, 00:00

  • Mental Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PRO25 COST OF HEALTHCARE RESOURCE UTILIZATION IN INTERSTITIAL LUNG DISEASES IN GERMANY IN 2017

    Nov 1, 2019, 00:00

  • PCN69 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TARGET DRUGS FOR SECOND-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PMD44 PRICING AND REIMBURSEMENT, AND MARKET ACCESS OF THERAPEUTIC MATERIALS (MEDICAL DEVICES/DIAGNOSTICS/BIOMARKERS) IN SOUTH KOREA.

    Nov 1, 2019, 00:00

  • PNS328 REAL OPTIONS ANALYSIS FOR MORE OPTIMALLY INFORMED REIMBURSEMENT DECISIONS

    Nov 1, 2019, 00:00

  • PCN456 REAL WORLD HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR FIRST LINE RECURRENT/ METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) PATIENTS

    Nov 1, 2019, 00:00

  • PIN108 THE BURDEN OF EBOLA VIRUS DISEASE (EVD) IN AFRICA: NEED FOR VACCINE (A TARGETED LITERATURE REVIEW)

    Nov 1, 2019, 00:00

  • PDB2 USING REAL WORLD DATA TO EXAMINE TRIGLYCERIDES, LDL-CHOLESTEROL, AND HDL-CHOLESTEROL AS PREDICTORS OF PROGRESSION FROM NONALCOHOLIC STEATOHEPATITIS TO HEPATOCELLULAR CANCER AND LIVER CIRRHOSIS

    Nov 1, 2019, 00:00

  • PND57 INFORMAL CARE COST IN NEUROLOGIC DISORDERS WITH THE CONTINGENT VALUATION METHOD

    Nov 1, 2019, 00:00

  • PDG52 CONSISTENCY OF NEW DRUG PRICING IN KOREA: BRIDGING VARIATIONS AMONG PERSONNEL IN PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PMS69 EFFECT OF HIP FLEXION CONTRACTURE ON TERMINAL STANCE OF GAIT AMONG INACTIVE UNIVERSITY STUDENTS

    Nov 1, 2019, 00:00

  • PND81 LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE

    Nov 1, 2019, 00:00

  • PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.

    Nov 1, 2019, 00:00

  • ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE

    Nov 1, 2019, 00:00

  • Alternative Medicine Process of Care

    Nov 1, 2019, 00:00

  • PMH33 COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY

    Nov 1, 2019, 00:00

  • PIN40 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCV30 COST-EFFECTIVENESS OF NOACS IN PATIENTS WITH ATRIAL FIBRILLATION: USING REAL-WORLD DATA FOR EXTERNAL VALIDATION

    Nov 1, 2019, 00:00

  • PNS269 PERSPECTIVES ON PRICING AND REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE GREEK HEALTHCARE SETTING: A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • PRO72 MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT

    Nov 1, 2019, 00:00

  • PMD42 THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS: A PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA?

    Nov 1, 2019, 00:00

  • PNS158 HEALTH ECONOMIC VALUE OF BLOOD IN SUB-SAHARAN AFRICA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE

    Nov 1, 2019, 00:00

  • PMU88 WHAT IS THE ROLE OF THE COMPANY EVIDENCE SUBMISSION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) MULTIPLE TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PIN84 KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN MAINLAND UNITED STATES (US) AND NON-MAINLAND US (PUERTO RICO AND WEST INDIES

    Nov 1, 2019, 00:00

  • PRS17 COST-EFFECTIVENESS OF A HYPOTHETICAL SCREENING PROGRAM FOR LUNG CANCER AND CARDIOVASCULAR DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • PCN326 ASSESSMENT OF THE ONCOLOGICAL OFFER AMONG ITALIAN REGIONS: A PATIENT-CENTERED ANALYSIS

    Nov 1, 2019, 00:00

  • HT3 WHAT INFLUENCES THE PROBABILITY TO BE SUCCESSFUL IN AN ONCOLOGY HTA? AN ANALYSIS OF ONCOLOGY HTA DECISIONS IN GERMANY, SPAIN AND THE UK

    Nov 1, 2019, 00:00

  • PNS313 A SYSTEMATIC REVIEW OF PATIENT EXPERIENCE DATA CAPTURED IN CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PCN279 EFFECT OF THE CHANGE IN COST-EFFECTIVENESS THRESHOLD ON THE NEWLY LISTED ANTICANCER DRUG PRICES IN THE NATIONAL HEALTH INSURANCE OF SOUTH KOREA

    Nov 1, 2019, 00:00

  • PIH18 PREDICTED COST AND CAPACITY BENEFITS OF THE DIGITALIZED SECONDARY CARE PATH FOR WOMEN WITH ENDOMETRIOSIS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • PDB117 PATIENT TREATMENT SATISFACTION AND STUDY STAFF PERCEPTIONS OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PCN316 TREATMENT PATTERNS OF ADVANCED SOFT-TISSUE SARCOMA IN ARGENTINA

    Nov 1, 2019, 00:00

  • PCN25 IMPACT OF GEMTUZUMAB OZOGAMICIN ON THE IRISH HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • Mental Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDG15 EFFICIENCY AND PRODUCTION OF THE AREA OF PREPARATION OF INTRAVENOUS ADMIXTURES AND STERILE MEDICATIONS

    Nov 1, 2019, 00:00

  • PCN321 IMAGING SURVEILLANCE OF PATIENTS WITH OVARIAN CANCER AFTER SUCCEEDING EARLY TREATMENT: A CROSS-SECTIONAL ANALYSIS FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PDG38 RELATIONSHIP BETWEEN RELIGIOSITY-SPIRITUALITY AND MEDICATION ADHERENCE AMONG PATIENTS WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN382 TRASTUZUMAB IN THE TREATMENT OF HER2-POSITIVE EARLY ANDLOCALLY ADVANCED BREAST CANCER: THE FIRST HTA REPORT OF INEAS-TUNISIA

    Nov 1, 2019, 00:00

  • PNS304 IN SEARCH OF A PAN-EUROPEAN VALUE SET; APPLICATION FOR EQ-5D-3L: THE PECUNIA PROJECT

    Nov 1, 2019, 00:00

  • PDB130 ECONOMIC BURDEN OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR THERAPIES: ANALYSIS OF NATIONAL SPECIALTY PHARMACY DATABASE

    Nov 1, 2019, 00:00

  • PSU17 ECONOMIC ANALYSIS OF SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCKADE IN LAPAROSCOPIC SURGERY IN CHINA

    Nov 1, 2019, 00:00

  • PRS23 COST-EFFECTIVENESS OF TIOTROPIUM + OLODATEROL VERSUS ACLIDINIUM + FORMOTEROL FIXED-DOSE COMBINATIONS IN THE MANAGEMENT OF MODERATE-TO-SEVERE COPD IN IRAN

    Nov 1, 2019, 00:00

  • PNS279 ASSESSING THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS IN LINE WITH THE INDICATED PATIENT POPULATION

    Nov 1, 2019, 00:00

  • PCN512 PROGRESSION, OVERALL SURVIVAL, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY: A SWEDISH REGISTER-BASED STUDY

    Nov 1, 2019, 00:00

  • PMH38 IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH HYPONATREMIA IN PSYCHIATRIC PATIENTS: A CASE CONTROL STUDY

    Nov 1, 2019, 00:00

  • PNS308 METHODOLOGICAL APPROACHES FOR INCORPORATING INVESTIGATORS' CHOICE COMPARATOR ARMS INTO NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PIN109 DETERMINING THE BURDEN OF CARBAPENEM-RESISTANT GRAM-NEGATIVE INFECTIONS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION?

    Nov 1, 2019, 00:00

  • PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?

    Nov 1, 2019, 00:00

  • PPM4 COMPREHENSIVE GENOMIC PROFILING FOR NON-SMALL CELL LUNG CANCER (NSCLC): A HEALTH AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PNS100 A STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING ADMINISTRATION OF PAEDIATRIC DOSAGE FORMS

    Nov 1, 2019, 00:00

  • PGI2 EVALUATION OF PATIENTS DEPRESCRIBED OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS USING KWAS QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY

    Nov 1, 2019, 00:00

  • PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

    Nov 1, 2019, 00:00

  • Toward a Smaller Design for EQ-5D-5L Valuation Studies

    Nov 1, 2019, 00:00

  • PCV58 TOTAL COSTS OF TREATMENT OF PATIENTS SUFFERING FROM VENOUS THROMBOEMBOLISM - IMPLICATIONS OF DIFFERENT COST PERSPECTIVES

    Nov 1, 2019, 00:00

  • PCN202 LIQUID BIOPSY FOR EGFR+ PATIENTS IN ADVANCED NSCLC: THE IMPACT OF DIFFERENT STRATEGIES

    Nov 1, 2019, 00:00

  • Medical Devices - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDG106 EFFECTS OF STATIN THERAPY ON LONG-TERM HEALTH CARE OUTCOMES AND MEDICAL COST-BASED ON CHINA REGIONAL HEALTH INSURANCE CLAIM DATABASE

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PRO133 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND PULMONARY ARTERIAL HYPERTENSION (PAH) DISEASE SEVERITY: A REVIEW OF GRIPHON, SERAPHIN, COMPASS-2 AND EARLY TRIALS

    Nov 1, 2019, 00:00

  • PMU37 NEWLY DIAGNOSED NONALCOHOLIC FATTY LIVER DISEASE AFTER BARIATRIC SURGERY: A STUDY OF ELECTRONIC MEDICAL RECORD DATA

    Nov 1, 2019, 00:00

  • PCN317 VALIDATION OF A STANDARD SET OF PATIENT-CENTERED OUTCOMES FOR LUNG CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN315 USE OF NOVEL HORMONAL AGENTS IN THE MONTH BEFORE DYING IN MEN DYING OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Nov 1, 2019, 00:00

  • PBI55 FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US

    Nov 1, 2019, 00:00

  • SP3 PATIENTS' PREFERENCES FOR BREAST CANCER TREATMENTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY FROM SPAIN, FRANCE, POLAND AND IRELAND

    Nov 1, 2019, 00:00

  • PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION

    Nov 1, 2019, 00:00

  • RARE Statistical Research

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG29 ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PMU5 ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS WITH HEPATIC DISEASES AT THE DEPARTMENT OF GASTROENTEROLOGY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PND70 NARCOLEPSY TREATMENT IN SWEDEN: REGISTER BASED STUDY

    Nov 1, 2019, 00:00

  • PNS259 NATIONAL HTA IMPLEMENTATION IN MIDDLE-INCOME COUNTRIES, THE CASE OF JORDAN

    Nov 1, 2019, 00:00

  • PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 ...

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43 (current)
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »